MediGene AG (MDG1):企業の財務・戦略的SWOT分析

【英語タイトル】MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(DATA904C0580)・商品コード:DATA904C0580
・発行会社(調査会社):GlobalData
・発行日:2018年7月
・ページ数:52
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

MediGene AG (MDG1) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MediGene AG (MediGene) is a biotechnology company which develops drugs for the treatment of various types and stages of cancer with candidates in clinical and pre-clinical development. The company focuses on the development of personalized T-cell-based immunotherapies. Its core business develops three immunotherapy platforms including DC vaccines to kill tumor cells; T-cell receptor (TCR) detects and kills tumor cells and T-cell-specific monoclonal antibodies (TAB’s), helps to remove unwanted T cells from the body. MediGene also has one marketed drug, Veregen for the treatment of genital warts. The company has operational presence in US, Europe and Asia. Medigene is headquartered in Martinsried, Germany.

MediGene AG Key Recent Developments

May 09,2018: Medigene reports First Quarter 2018 financials and provides operational update
Apr 11,2018: Medigene appoints Dr. Kai Pinkernell to the Executive Management Board as CMO/CDO
Mar 22,2018: Medigene publishes 2017 annual report
Mar 06,2018: Medigene strengthens its patent portfolio with a European patent covering T cell identification method
Feb 02,2018: Medigene strengthens its patent portfolio with a US patent on a tagged TCR

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
MediGene AG – Key Facts 5
MediGene AG – Key Employees 6
MediGene AG – Key Employee Biographies 7
MediGene AG – Major Products and Services 8
MediGene AG – History 9
MediGene AG – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Section 2 – Company Analysis 17
Company Overview 17
MediGene AG – Business Description 18
MediGene AG – SWOT Analysis 19
SWOT Analysis – Overview 19
MediGene AG – Strengths 19
MediGene AG – Weaknesses 20
MediGene AG – Opportunities 21
MediGene AG – Threats 22
MediGene AG – Key Competitors 23
Section 3 – Company Financial Ratios 24
Financial Ratios – Capital Market Ratios 24
Financial Ratios – Annual Ratios 25
Performance Chart 27
Financial Performance 27
Financial Ratios – Interim Ratios 28
Financial Ratios – Ratio Charts 29
Section 4 – Company’s Lifesciences Financial Deals and Alliances 30
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
MediGene AG, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31
MediGene AG, Recent Deals Summary 32
Section 5 – Company’s Recent Developments 33
May 09, 2018: Medigene reports First Quarter 2018 financials and provides operational update 33
Apr 11, 2018: Medigene appoints Dr. Kai Pinkernell to the Executive Management Board as CMO/CDO 35
Mar 22, 2018: Medigene publishes 2017 annual report 36
Mar 06, 2018: Medigene strengthens its patent portfolio with a European patent covering T cell identification method 39
Feb 02, 2018: Medigene strengthens its patent portfolio with a US patent on a tagged TCR 40
Jan 19, 2018: Medigene announces participation at six upcoming investor and scientific conferences 41
Jan 04, 2018: Expitope 2.0 Helps to Identify Safer Antigens for Immunotherapy of Cancer 42
Dec 12, 2017: How Immunotherapy of Cancer May Create Novel Clinical Utilities for HLA Typing 43
Nov 09, 2017: Medigene Reports Nine Months’ Results 2017 45
Aug 25, 2017: Medigene Announces Participation At Five Upcoming Scientific And Investor Conferences 47
Section 6 – Appendix 48
Methodology 48
Ratio Definitions 48
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
MediGene AG, Key Facts 5
MediGene AG, Key Employees 6
MediGene AG, Key Employee Biographies 7
MediGene AG, Major Products and Services 8
MediGene AG, History 9
MediGene AG, Subsidiaries 16
MediGene AG, Key Competitors 23
MediGene AG, Ratios based on current share price 24
MediGene AG, Annual Ratios 25
MediGene AG, Annual Ratios (Cont...1) 26
MediGene AG, Interim Ratios 28
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
MediGene AG, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31
MediGene AG, Recent Deals Summary 32
Currency Codes 48
Capital Market Ratios 48
Equity Ratios 49
Profitability Ratios 49
Cost Ratios 50
Liquidity Ratios 50
Leverage Ratios 51
Efficiency Ratios 51

List of Figures
MediGene AG, Performance Chart (2013 - 2017) 27
MediGene AG, Ratio Charts 29
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
MediGene AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 31

★調査レポート[MediGene AG (MDG1):企業の財務・戦略的SWOT分析] (コード:DATA904C0580)販売に関する免責事項を必ずご確認ください。
★調査レポート[MediGene AG (MDG1):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆